ClinicalTrials.gg
Not yet recruitingNCT07943559Updated Nov 17, 2026

Mechanisms and Interventions of Treatment-Resistant Schizophrenia Based on Brain Organoids

An observational study in Treatment-resistant Schizophrenia, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Mental Health Center · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
10
Sex
All
01

Study summary

Approximately 20-30% of patients with schizophrenia show poor response to standard antipsychotic medications, which is defined as treatment- resistant schizophrenia (TRS), yet the underlying pathological mechanisms remain largely unknown. Brain organoids, also referred to as cerebral organoids, have emerged as a promising tool for modeling neurodevelopmental disorders in the laboratory. In this observational study, blood samples will be collected from TRS patients and their family members to generate personalized brain organoids. This study aims to elucidate the mechanisms of TRS and to provide preclinical evidence for developing personalized intervention strategies.

Read the detailed description

This study investigates early-onset treatment-resistant schizophrenia using personalized brain organoids. Blood samples will be collected from patients with schizophrenia and their family members to obtain peripheral blood mononuclear cells (PBMCs). Induced pluripotent stem cells (iPSCs) will be reprogrammed from these PBMCs and differentiated into brain organoids that mimic individual brain development. Multi-omics analyses will be performed on these models to explore the biological heterogeneity underlying TRS. Various drugs will be tested on the organoids to identify which medications are effective for each patient. Clinical data including symptoms and cognition will be collected and integrated with laboratory findings. This study aims to provide preclinical evidence for developing personalized targeted interventions for TRS and to establish a foundation for future precision medicine clinical trials in this population.

02

Conditions studied

  • Treatment-resistant Schizophrenia

Keywords

  • schizophrenia
  • treatment-resistant
  • brain organoids
03

In context

Schizophrenia, Treatment-Resistant

53 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 22 are open to participants now.

Browse Schizophrenia, Treatment-Resistant studies →

Lead sponsor

Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 96 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with early-onset treatment-resistant schizophrenia and their first-degree relatives will be recruited from inpatient units at Shanghai Mental Health Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria for schizophrenia
  2. Meets the diagnostic criteria for early-onset schizophrenia (age of onset \< 18 years)
  3. Meet the diagnostic criteria for treatment-resistant schizophrenia, defined as:

    • Inadequate response from adequate trials of two different classes of antipsychotic drugs (≥ 600 mg/day chlorpromazine equivalents), at least 6 weeks
    • Persistence of positive symptoms,defined as a score of ≥ 4 on at least two items, or a score of ≥ 6 on at least one item, of the positive subscale of the PANSS
    • At least moderate functional impairment, as indicated by a PSP score ≤ 70
  4. Written ;

Exclusion criteria

Exclusion Criteria:

  1. Current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnant or lactation;
  2. Uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc.;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
10 participants (estimated)
Target follow-up
8 Weeks
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Association Between Organoid-derived Biological Characteristics and Clinical Phenotypes

    The associations between biological characteristics of patient-derived brain organoids and clinical phenotypes of patients with early-onset treatment-resistant schizophrenia (EO-TRS) will be investigated. Psychiatric symptom severity will be assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function will be evaluated using the MATRICS Consensus Cognitive Battery (MCCB). The biological characteristics of brain organoids will be evaluated through transcriptomic and morphological analyses. Transcriptomic analyses will be performed to identify differentially expressed genes across organoids from different patients, while morphological analyses will assess neuronal structure and synaptic formation. Correlation analyses will be conducted to explore the relationships between organoid-derived biological features and clinical symptom severity and cognitive performance.

    Time frame: At baseline clinical assessment and corresponding brain organoid characterization

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943559
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Dengtang Liu
Contact
liudengtang@smhc.org.cn
021-34773434

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion